What happened
A study published on 6 June 2026 in the Journal of the American Heart Association, timed to the big diabetes meeting, looked at more than 26,000 adults who had both obesity and an autoimmune disease, and compared those on a GLP-1 with those who were not.
The differences were large. GLP-1 users had a 44% lower risk of dying from any cause, a 31% lower risk of a dangerous lung clot (pulmonary embolism), a 21% lower risk of an emergency-room visit, and a 17% lower risk of blood clots in the veins.
Why this is a women's story
Autoimmune diseases are not evenly shared. Conditions like lupus, rheumatoid arthritis, Hashimoto's thyroid disease and multiple sclerosis fall disproportionately on women, often two to nine times more often than on men. These are also conditions that carry a quietly raised risk of heart disease and clots, partly from the chronic inflammation they cause.
So a finding that GLP-1s may lower death and cardiovascular risk specifically in people with autoimmune disease is, in practice, a finding about a population that is mostly women. That is rare, and worth noticing.
The likely reason: inflammation
This study cannot prove the drug caused the benefit, observational studies never can. But the leading explanation fits a growing pattern. Autoimmune diseases run on inflammation, and inflammation drives heart disease and clots. GLP-1 medications appear to lower inflammation, both by reducing excess fat and through more direct effects. Calm the inflammation, and you may calm the risks that ride on it. (We go deeper on this in how GLP-1s calm inflammation.)
What it means for you
If you live with an autoimmune condition and obesity, this is an encouraging signal worth raising with your doctor, not a reason to change anything on your own. The decision about a GLP-1 still belongs in that conversation, weighed against your full history.
The broader lesson is the one that keeps repeating in 2026: the benefits of these drugs reach well beyond the scale, into the heart, the blood, and the immune system. The number on the scale is the least of it.
What Steady does with this
Steady cannot treat your autoimmune disease, and it would never claim to. What it does is help you use your medication well and notice your body clearly, which matters more, not less, when you are managing more than one condition at once.
- It tracks fourteen symptoms on a severity slider, including fatigue and mood, the very symptoms that blur the line between a flare and a side effect.
- It keeps your dose, weight and symptoms in one timeline, so your rheumatologist or GP and your prescriber are reading the same story.
- It reads your cycle alongside your dose, because hormones and autoimmune symptoms move together more than most apps admit.
The scale cannot see inflammation. Steady is built around the parts of your health the scale never shows.
